AI MARKET SCANNING

Acumen Pharmaceuticals, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.84%
MAX GAP RECORD +8.95%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ABOS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Oct 26, 2026 Earnings Release 2026-10-26 (BEFORE OPEN (08:00))
+7.58%
Aug 12, 2026 Earnings Release 2026-08-12 (BEFORE OPEN)
-2.43%
May 12, 2026 Earnings Release 2026-05-12 (BEFORE OPEN)
+0.39%
Mar 26, 2026 Earnings Release 2026-03-26 (BEFORE OPEN)
-2.66%
Nov 12, 2025 Earnings Release 2025-11-12 (BEFORE OPEN)
+0.51%
Aug 12, 2025 Earnings Release 2025-08-12 (BEFORE OPEN)
-0.70%
May 13, 2025 Earnings Release 2025-05-13 (BEFORE OPEN)
+0.00%
Mar 27, 2025 Earnings Release 2025-03-27 (BEFORE OPEN)
+7.76%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.8%
Bullish Gaps (5)
Bearish Gaps (4)
Neutral / Flat (5)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ABOS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗